EQS-Adhoc: Ad hoc: Cantourage significantly increases profitability and revenue – EBITDA margin of 11 to 13% in the first quarter of 2025

Not for direct or indirect publication or distribution within or in the United States of America, Australia, Canada or Japan or any other jurisdiction where such publication or distribution would be unlawful. Please note the important information at the end of this announcement.

Ad hoc: Cantourage significantly increases profitability and revenue – EBITDA margin of 11 to 13% in the first quarter of 2025

Berlin, 20 May 2025 - Cantourage Group SE (hereinafter ‘Cantourage’, ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading listed medical cannabis company, reports an EBITDA margin of 11 to 13% for the first quarter of 2025 based on preliminary internal figures (unaudited, non-consolidated). Revenue for the same period amounted to more than EUR 25 million; cumulative revenue at the end of April was already over EUR 36 million. Cantourage thus confirms both the economic scalability of its business model and the continued strong demand in its core markets.

About Cantourage:
Cantourage is a leading European company in the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since 11 November 2022 and trades under the ticker symbol ‘HIGH’.

Press contacts:
Pia Senkel | pia.senkel@tonka-pr.com | +49 (0) 173 3702649
Klaas Geller | klaas.geller@tonka-communications.de | +49 (0) 176 74717519

Important information:
This announcement contains information within the meaning of Article 17 of Regulation (EU) No. 596/2014 (Market Abuse Regulation).
This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This ad hoc announcement was published via the electronic information distribution service EQS News.